HIKAL
Double Top Buy triggered today above 707.72 daily close on 3% Box Size chart.
Hybrid CDMO! https://t.co/SHqEUZG0WP

HIKAL
— Saket Reddy (@saketreddy) July 20, 2021
Double Top Buy triggered above 554.72 daily close on 1% Box Size chart. pic.twitter.com/70Ajvt8dtZ
More from Saket Reddy
While people were debating figuring out which is the best in ICICI/AXIS & INDUSINDBNK, look what the top 3 high quality banks (HDFCBANK, KOTAKBANK & CUB) have done over the last 5, 10 & 17 years.
They are the real compounders, they've created massive wealth compared to others! https://t.co/PluVwU5OXG
They are the real compounders, they've created massive wealth compared to others! https://t.co/PluVwU5OXG

Hope Everyone saw BANDHANBNK Numbers. I feel many such banks will go through a massive NPA Cycle followed by depleted Tier 1.
— Saket Reddy (@saketreddy) January 24, 2021
Hence, stay with the Top 3 banks :-
HDFCBANK
KOTAKBANK
CUB
They've low cost of funding, well provisioned Moratorium book, high ROEs & high Tier 1 CAR.
KPRMILL
Double Top Buy triggered above 459.17 (2295 Pre Split) daily close on 1% Box Size chart. https://t.co/0jUBx6hKMI
Double Top Buy triggered above 459.17 (2295 Pre Split) daily close on 1% Box Size chart. https://t.co/0jUBx6hKMI

KPRMILL
— Saket Reddy (@saketreddy) September 3, 2021
Double Top Buy & T20 Pattern - Bullish above 2051.18 daily close on 3% Box Size chart. https://t.co/bJgLA1BGuv pic.twitter.com/xpTKy6vnBT
More from Hikal
Key insights from Hikal
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa

Hikal: Strong
— JST Investments (@JstInvestments) August 5, 2021
\U0001f9ea Rev up 27% YoY
\U0001f9ea 22% EBITDA margin
\U0001f9ea Pat of 50crs
\U0001f9ea Growth across both pharmaceuticals & crop protection.#Q1withJST #Pharma pic.twitter.com/8lFo68KzPe